Reslizumab Overview

Introduction of Reslizumab

Reslizumab (previously Sch 55700) is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. Developed by Teva Pharmaceuticals, reslizumab indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype. With the brand name Cinqair, reslizumab was approved by the FDA in March 2016.

Mechanism of Action of Reslizumab

As eosinophils are the dominating effector cells in asthma, inhibition of eosinophilia, theoretically would result in a decreased airway injury, mucus hypersecretion and bronchial hyper-responsiveness. IL-5 induces an inflammatory response by interacting with eosinophils through targeting the Interleukin-5 receptor (IL-5R) expressed in eosinophils, basophils and some mast cells. Reslizumab is a humanized monoclonal antibody that targets IL-5. It occupies the region ERRR (glutamic acid, arginine, arginine, arginine) corresponding to amino acids 89–92 on IL-5, which is critical for its interaction with the receptor with subsequent inhibition of IL-5 bioactivity. Blocking of IL-5 signalling thereby reduces the production and survival of eosinophils and inhibits eosinophilic-driven inflammation.

Figure 1 Mechanism of Action of Reslizumab

Clinical Projects of Reslizumab *

Approved Drugs of Reslizumab **

INN (trade name)	Therapeutic area	Dose	Strength	Route	Company	Marketing start	Market
Cinqaero	Severe eosinophilic asthma aged 18 years and older	Injection, concentrated	10mg/ 1mL	Intravenous Infusion	Teva Pharma Australia Pty Ltd	July 25, 2017
Cinqair	Severe eosinophilic asthma aged 18 years and older	Injectable	10mg/ 1mL	Intravenous Infusion	Teva Respiratory LLC	March 2, 2016
Cinqair	Severe eosinophilic asthma aged 18 years and older	Lolution	10mg	Intravenous Infusion	Teva	December 19, 2016

What We Provide

Therapeutic Antibody

Reslizumab

We provide high-quality Reslizumab for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Resources
* The table was excerpted from the following website
https://clinicaltrials.gov/ct2/results?cond=&term=Reslizumab&cntry=&state=&city=&dist=

** Information presented in the table were collected from the following websites:
http://search.tga.gov.au/s/search.html?query=reslizumab&collection=tgaartg&profile=record
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761033Orig1s000SumR.pdf
https://www.drugbank.ca/drugs/DB06602

For research use only. Not intended for any clinical use.